|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-3-1
|
|
pubmed:abstractText |
Dacarbazine (DTIC) is the first-line chemotherapy for metastatic malignant melanoma without cerebral metastasis. Its clinical and hematological safety is usually good. Hypersensitivity in hepatic failure patients is the most serious side effect described.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0151-9638
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
133
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
157-60
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16508601-Adult,
pubmed-meshheading:16508601-Aged,
pubmed-meshheading:16508601-Aged, 80 and over,
pubmed-meshheading:16508601-Anemia, Aplastic,
pubmed-meshheading:16508601-Antineoplastic Agents, Alkylating,
pubmed-meshheading:16508601-Cross-Sectional Studies,
pubmed-meshheading:16508601-Dacarbazine,
pubmed-meshheading:16508601-Drug Hypersensitivity,
pubmed-meshheading:16508601-Female,
pubmed-meshheading:16508601-Humans,
pubmed-meshheading:16508601-Lymphatic Metastasis,
pubmed-meshheading:16508601-Male,
pubmed-meshheading:16508601-Melanoma,
pubmed-meshheading:16508601-Middle Aged,
pubmed-meshheading:16508601-Neoplasm Metastasis,
pubmed-meshheading:16508601-Retrospective Studies,
pubmed-meshheading:16508601-Skin Neoplasms,
pubmed-meshheading:16508601-Time Factors
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
[Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
|
|
pubmed:affiliation |
Service de Dermatologie I, Hôpital Saint-Louis, Paris.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
